Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 449 (ZNF449) is a nuclear transcription factor characterized by an N-terminal SCAN domain and seven C2H2-type zinc finger motifs at its C-terminus[1][4][2]. It is ubiquitously expressed in human tissues and localizes to the nucleus, aligning with its predicted role in gene transcription regulation[1]. ZNF449 can transactivate enhancers or promoters of chondrogenic genes, such as SOX6, SOX9, and COL2A1, facilitating early chondrogenic differentiation from mesenchymal stem cells[1][2]. Mouse knockout studies suggest that while ZNF449 participates in early chondrogenesis, loss of the protein does not result in overt skeletal abnormalities, possibly due to functional redundancy within zinc finger family members[2]. Currently, there is no evidence supporting a role of ZNF449 as a therapeutic target or drug receptor, nor are there associated biomarkers or direct disease links identified in humans[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 449 (ZNF449).